Orient EuroPharma Co., Ltd. (TPEX:4120)
Taiwan · Delayed Price · Currency is TWD 44.15
+0.40 (0.91%)
Feb 11, 2026, 1:30 PM CST
Orient EuroPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 4,531 | 4,391 | 4,592 | 4,730 | 4,767 | 5,384 | |
Revenue Growth (YoY) | 1.36% | -4.37% | -2.93% | -0.77% | -11.45% | -11.65% |
Cost of Revenue | 2,331 | 2,325 | 2,445 | 2,698 | 2,616 | 2,962 |
Gross Profit | 2,201 | 2,066 | 2,147 | 2,032 | 2,151 | 2,422 |
Selling, General & Admin | 1,882 | 1,811 | 1,868 | 1,922 | 1,918 | 1,938 |
Research & Development | 407.07 | 242.22 | 206.6 | 259.84 | 331.09 | 366.56 |
Operating Expenses | 2,304 | 2,073 | 2,077 | 2,182 | 2,246 | 2,305 |
Operating Income | -103.04 | -6.72 | 70.61 | -149.54 | -95.68 | 117.36 |
Interest Expense | -87.23 | -107.23 | -106.1 | -69.53 | -38.04 | -30.23 |
Interest & Investment Income | 31.93 | 48.87 | 50.86 | 20.96 | 11.85 | 16.04 |
Earnings From Equity Investments | -55.54 | -27.29 | -18.27 | -30.14 | -19.14 | -16.88 |
Currency Exchange Gain (Loss) | -29.38 | -111.86 | -25.59 | -177.51 | 11.6 | 125.63 |
Other Non Operating Income (Expenses) | 62.24 | 71.11 | 50.08 | 40.54 | 41.69 | 36.45 |
EBT Excluding Unusual Items | -181.02 | -133.1 | 21.6 | -365.23 | -87.71 | 248.36 |
Gain (Loss) on Sale of Investments | 6.15 | 6.15 | - | - | - | - |
Gain (Loss) on Sale of Assets | 2.81 | -4.83 | 234.5 | 72.35 | 182.38 | 1.07 |
Asset Writedown | - | - | - | -35.3 | -10 | - |
Other Unusual Items | 0.22 | 1.8 | 0.16 | 0.05 | 0.1 | 0.46 |
Pretax Income | -171.85 | -129.99 | 256.25 | -328.14 | 84.77 | 249.88 |
Income Tax Expense | 231.32 | 101.21 | 86.97 | -32.77 | 10.47 | 143.01 |
Earnings From Continuing Operations | -403.17 | -231.2 | 169.29 | -295.37 | 74.3 | 106.88 |
Minority Interest in Earnings | -60.01 | -52.74 | -25.34 | -15.44 | 45.88 | 92.43 |
Net Income | -463.18 | -283.93 | 143.94 | -310.8 | 120.17 | 199.3 |
Net Income to Common | -463.18 | -283.93 | 143.94 | -310.8 | 120.17 | 199.3 |
Net Income Growth | - | - | - | - | -39.70% | -19.53% |
Shares Outstanding (Basic) | 87 | 87 | 87 | 87 | 87 | 87 |
Shares Outstanding (Diluted) | 87 | 87 | 87 | 87 | 87 | 87 |
Shares Change (YoY) | -0.23% | -0.23% | 0.23% | -0.24% | -0.21% | 0.07% |
EPS (Basic) | -5.34 | -3.27 | 1.66 | -3.58 | 1.39 | 2.30 |
EPS (Diluted) | -5.34 | -3.27 | 1.66 | -3.58 | 1.38 | 2.29 |
EPS Growth | - | - | - | - | -39.74% | -19.37% |
Free Cash Flow | -228.45 | -220.16 | -34.73 | -857.91 | -1,485 | 375.77 |
Free Cash Flow Per Share | -2.63 | -2.54 | -0.40 | -9.89 | -17.08 | 4.31 |
Dividend Per Share | 1.000 | 1.000 | 1.000 | - | 0.850 | 1.500 |
Dividend Growth | - | - | - | - | -43.33% | -16.67% |
Gross Margin | 48.56% | 47.05% | 46.76% | 42.96% | 45.12% | 44.99% |
Operating Margin | -2.27% | -0.15% | 1.54% | -3.16% | -2.01% | 2.18% |
Profit Margin | -10.22% | -6.47% | 3.14% | -6.57% | 2.52% | 3.70% |
Free Cash Flow Margin | -5.04% | -5.01% | -0.76% | -18.14% | -31.16% | 6.98% |
EBITDA | 51.54 | 153.46 | 235.75 | 7.04 | 60.33 | 278.32 |
EBITDA Margin | 1.14% | 3.50% | 5.13% | 0.15% | 1.27% | 5.17% |
D&A For EBITDA | 154.58 | 160.18 | 165.14 | 156.57 | 156.01 | 160.97 |
EBIT | -103.04 | -6.72 | 70.61 | -149.54 | -95.68 | 117.36 |
EBIT Margin | -2.27% | -0.15% | 1.54% | -3.16% | -2.01% | 2.18% |
Effective Tax Rate | - | - | 33.94% | - | 12.35% | 57.23% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.